Mr. Biondi reportedly left to become an executive partner at Flagship Pioneering, a company that builds life sciences companies.
The departure was unexpected, as Mr. Biondi was named to be head of strategy and business development for the expanded company once it formally acquires Celgene for $74 billion.
Mr. Biondi had been part of Bristol-Myers Squibb for 17 years and helped the company secure billions of dollars in deals, including a $1.85 billion cancer drug alliance with Nektar Therapeutics, according to Endpoints News.
Read the full article here.
More articles on pharmacy:
House passes Pelosi’s drug pricing bill, with a few changes
Walmart agrees to continue accepting paper prescriptions
Sienna Biopharmaceuticals to shut down by end of week
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.